Popular blood-thinner Xarelto (rivaroxaban) has been approved by the FDA to reduce the risk of venous thromboembolism (VTE). The 10mg once daily dosage is to be prescribed following six months of initial anticoagulation therapy, and is being touted in the medical community as the go-to blood thinner over aspirin.
Manufacturer Janssen Pharmaceuticals explained their use of the EINSTEIN CHOICE study, “a Phase 3, global, randomized, double-blind, superiority study that compared the efficacy and safety of two doses of XARELTO® (10 mg and 20 mg once daily) with aspirin 100 mg once daily for the management of VTE.”
